Stenabolic comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
== Voting == OECD decisions are made through voting, which requires unanimity among all of those voting. Each member country has one vote. However, dissenting members which do not wish to block a decision but merely to signal their disapproval can abstain from voting. 22 of the OECD member countries are also EU member states.
Peroxidases or peroxide reductases (EC number 1.11.1.x) are a large group of enzymes which play a role in various biological processes. They are named after the fact that they commonly break up peroxides, and should not be confused with other enzymes that produce peroxide, which are often oxidases.
Cyclophosphamide is a common cytotoxic drug used in this manner and is often used in conjunction with total body irradiation. Chemotherapeutic drugs may be used at high doses to permanently remove the recipient's bone marrow cells (myeloablative conditioning) or at lower doses that will prevent permanent bone marrow loss (non-myeloablative and reduced intensity conditioning). When used in non-cancer setting, the treatment is still called "chemotherapy", and is often done in the same treatment centers used for people with cancer.
=== Apodization in photography === Most camera lenses contain diaphragms which decrease the amount of light coming into the camera. These are not strictly an example of apodization, since the diaphragm does not produce a smooth transition to zero intensity, nor does it shape the intensity profile beyond the "top hat" transmission of its aperture. Some lenses use other methods to reduce the amount of light let in. For example, the Minolta/Sony STF 135mm f/2.8 T4.5 lens has a special design which accomplishes this by using a concave neutral-gray-tinted lens element as an apodization filter, thereby producing a pleasant bokeh. The same optical effect can be achieved by combining depth-of-field bracketing with multiple exposure, as implemented in the Minolta Maxxum 7's STF function. In 2014, Fujifilm announced a lens utilizing a similar apodization filter in the Fujinon XF 56mm F1.2 R APD lens. In 2017, Sony introduced the E-mount full-frame lens Sony FE 100mm F2.8 STF GM OSS (SEL-100F28GM) based on the same optical Smooth Trans Focus principle. Simulation of a Gaussian laser beam input profile is also an example of apodization. Photon sieves provide a relatively easy way to achieve tailored optical apodization.
Sources: en.wikipedia.org
Non-contact normothermic (or nonthermal) wound therapy, also called The Warm-Up Therapy System or wound therapy with infrared radiation, is the process of increasing the temperature of the wound bed, thereby promoting increased blood flow in the area around the wound. It is a temporary therapy (usually about 72 hours for each time usage) in which the dressing contains a special electronic warming card. The card heats to 100.4 °F (38 °C), bathing the wound in radiant heat. The closely sealed wound covering promotes a moist environment in the wound bed. It is sometimes indicated in wounds that have failed to heal with conventional therapies including wounds with compromised blood flow, diabetic ulcers, and bed sores.
Another advantage is the accuracy of the method. In an analysis performed by Li et al., it was found that use of fluorescence detection techniques yielded 100% detection accuracy in 13 of 15 collected images. The remaining two had relative errors around 6%. Another advantage of fluorescence detection is that it allows for quantitative analysis of droplet spacing in a sample. This is done by use of temporal measurements and the flow velocity of the analyte. The time spacing between signals allows for calculation of droplet spacing. Further fluorescence analysis of microfluidic droplet samples can be used to measure the fluorescent lifetime of samples, providing additional information that is not obtainable for fluorescence intensity measurements alone. The applications of fluorescence detection are varied, with many of its uses centered in biological applications. Frenz et al. utilized fluorescence detection of droplets to examine enzyme kinetics. For this experiment, b-lactamase interacted with fluorocillin, a fluorogenic substrate. Fluorescence of the droplets was measured at multiple time intervals to examine the change with time. This detection method goes beyond biological applications, though, and allows for the physical study of droplet formation and evolution. For example, Sakai et al. used fluorescence detection to monitor droplet size. This was done by collecting fluorescence data to calculate the concentration of a fluorescent dye within a single droplet, thus allowing size growth to be monitored.
GABAA receptor: positive allosteric modulator (primarily of δ subunit-containing receptors) NMDA receptor: negative allosteric modulator AMPA receptor: negative allosteric modulator Kainate receptor: negative allosteric modulator Glycine receptor: positive allosteric modulator Serotonin 5-HT3 receptor: positive allosteric modulator Opioid receptor: endogenous positive allosteric modulator Muscarinic acetylcholine receptor: positive allosteric modulator. Nicotinic acetylcholine receptor: positive allosteric modulator Glycine reuptake inhibitor Adenosine reuptake inhibitor L-type calcium channel: channel blocker GIRK: channel opener Voltage-gated calcium channel Dihydropyridine-sensitive L-type Ca2+ channels BK channel modulation G-protein-activated inwardly rectifying K+ channels Brain medulla: Decreased levels of nitric oxide Mesolimbic pathway: Increased levels of dopamine and endogenous opioids, secondary to other actions Many of these actions have been found to occur only at very high concentrations that may not be pharmacologically significant at recreational doses of ethanol, and it is unclear how or to what extent each of the individual actions is involved in the effects of ethanol. Some of the actions of ethanol on ligand-gated ion channels, specifically the nicotinic acetylcholine receptors and the glycine receptor, are dose-dependent, with potentiation or inhibition occurring dependent on ethanol concentration. This seems to be because the effects of ethanol on these channels are a summation of positive and negative allosteric modulatory actions.
Sources: en.wikipedia.org
== Adverse effects == The drug label (in some jurisdictions) has warnings with regard to the risk of respiratory depression, anticholinergic toxicity and opioid overdose, the risk of dehydration and electrolyte imbalance that people with severe diarrhea always run, and toxic megacolon in people with ulcerative colitis. Other adverse effects include numbness in the hands and feet, euphoria, depression, lethargy, confusion, drowsiness, dizziness, restlessness, headache, hallucinations, edema, hives, swollen gums, itchiness, vomiting, nausea, loss of appetite, and stomach pain.
di-β-phenylisopropylamine also known by the abbreviations DPIA or DPEA, or N,N-Di-β-phenylisopropylamine, and also under the code name Iem-1365, it is a central nervous system stimulant but, above all, a serotonergic agent that also exhibits adrenergic activity; it has been shown to cause central nervous system effects and toxicity similar to those of amphetamine. DPIA is a secondary amine; structurally, the molecule can be described as comprising a single central amine, to which two isopropyl chains with benzene rings at their ends are attached symmetrically on either side.
====== Pangenotypic direct-acting antiviral combinations ====== Daclatasvir Daclatasvir/sofosbuvir (daclatasvir + sofosbuvir) Glecaprevir/pibrentasvir (glecaprevir + pibrentasvir) Ravidasvir Sofosbuvir Sofosbuvir/velpatasvir (sofosbuvir + velpatasvir)
=== Countercurrent chromatography === Countercurrent chromatography (CCC) is a type of liquid-liquid chromatography, where both the stationary and mobile phases are liquids and the liquid stationary phase is held stagnant by a strong centrifugal force.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.